Treating Chromoblastomycosis: A Long-Term Strategy
At a Glance
Chromoblastomycosis usually needs months or years of individualized treatment. Small lesions may be removed surgically, while extensive disease often needs oral itraconazole or terbinafine, sometimes with physical treatments such as cryotherapy or laser and careful liver monitoring.
Treating chromoblastomycosis is often described as a marathon rather than a sprint. Because the fungus is exceptionally hardy and the muriform cells are protected by thick walls, standard treatment is highly individualized and usually lasts for many months, sometimes years [1][2]. There is no “one-size-fits-all” approach; instead, your care team will tailor a strategy based on the size, location, duration of your lesions, and the specific fungus involved [3][4].
Important Safety Note: Never start, stop, or combine antifungal medications or physical therapies on your own. Always involve a pharmacist or clinician when adding any new prescription, over-the-counter medicine, or supplement.
Categorizing the Approach
Doctors generally evaluate the disease extent to help build a treatment plan:
- Limited Disease: If you have a single, small, recent lesion that hasn’t spread, the goal is often removal through localized physical therapies, such as surgery [5][6].
- Extensive or Chronic Disease: If the infection is large, involves multiple sites, or has been present for many years, management typically requires a combination of long-term oral medications and adjunctive physical treatments [7][8].
Surgical and Physical Options
For localized infections, physical destruction of the fungus is a common route to a cure, and for larger lesions, these are often used alongside medication.
- Surgical Excision: This involves cutting out the infected tissue along with a “safety margin” of healthy skin to ensure no fungal cells remain [5]. While effective for small lesions, there is a risk that the fungus can recur at the edges of the surgical scar [9].
- Cryotherapy: Using liquid nitrogen to freeze the fungal cells. This is rarely used alone and is most effective when paired with oral antifungal medications, performed under careful medical supervision [10][11].
- Thermotherapy: The fungi that cause chromoblastomycosis are sensitive to heat. Applying controlled heat is sometimes used as an adjunct to inhibit fungal growth, but this must be specialist-supervised with a defined protocol and monitoring. Unsupervised heating with household equipment can cause severe burns or worsen ulcers [12][13].
- CO2 Laser: This can be used to “debulk” or flatten thick, warty lesions, making it easier for other treatments or medications to reach the deeper layers of the fungus [14][15].
Systemic Antifungal Medications
Many patients will require systemic therapy—medications taken by mouth that travel through the bloodstream to reach the fungus deep in the skin [7].
- Itraconazole: A very common option that works by disrupting the fungal cell membrane.
- Terbinafine: Another common option, sometimes used alone or in combination with itraconazole.
Crucial Medication Safety Considerations:
- Liver Monitoring: Both medications can cause liver injury. Standard care includes baseline and periodic blood tests to monitor your liver function, with the timing individualized by your doctor [16]. Alert your doctor immediately if you notice yellowing of the skin (jaundice), dark urine, persistent nausea, or extreme fatigue.
- Heart and Interaction Risks (Itraconazole): Itraconazole carries warnings regarding heart failure and has major interactions with the CYP3A4 liver enzyme system. It can dangerously alter the blood levels of many other drugs (including cholesterol drugs and blood thinners).
- Taste/Smell Changes (Terbinafine): Terbinafine can sometimes cause disturbances in your sense of taste or smell.
- Pregnancy and Complete Review: Your doctor should review your pregnancy status, any history of heart or liver disease, and every supplement or medication you take before starting therapy.
Understanding “Cure” and Relapse
Because chromoblastomycosis is so resistant, the goals of treatment are carefully defined:
- Clinical Cure: This means the active clinical disease has resolved (the skin looks clear of active infection), though it may leave substantial scar tissue [17].
- Mycological Cure: This means that fungal elements are no longer detected by the tests used (like biopsies or cultures). It does not necessarily guarantee that every single fungal cell is dead, as they can sometimes hide deep in scar tissue [2].
Even when both a clinical and mycological cure are declared, the risk of relapse is high [10][17]. For this reason, you should never stop treatment early just because the skin looks better. Long-term follow-up visits with your dermatologist are essential to ensure the fungus does not return [17].
Common questions in this guide
How long does treatment for chromoblastomycosis usually take?
Can surgery cure a small chromoblastomycosis lesion?
Which oral antifungal medicines are used for chromoblastomycosis?
What side effects or interactions should I discuss before taking itraconazole or terbinafine?
Can cryotherapy, heat treatment, or laser be combined with antifungal medicine?
How do doctors know whether chromoblastomycosis is cured?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Chromomycosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Do you classify my infection as 'limited' or 'extensive,' and how does that classification guide our starting treatment?
- 2.Am I a candidate for surgical excision, and if so, what is the risk of the fungus returning at the surgery site?
- 3.Which antifungal medication do you recommend—itraconazole or terbinafine—and what are the specific side effects I should watch for?
- 4.How often will we need to perform blood tests to monitor my liver function while I am on these medications?
- 5.What physical therapies, such as cryotherapy or laser, can we combine with my medication to improve the chances of a cure?
- 6.What is our goal for 'clinical cure' versus 'mycological cure,' and how long after the skin looks clear should I continue treatment?
References
References (17)
- 1
Chromoblastomycosis in the Amazon region, Brazil, caused by Fonsecaea pedrosoi, Fonsecaea nubica, and Rhinocladiella similis: Clinicopathology, susceptibility, and molecular identification.
de Andrade TS, de Almeida AMZ, Basano SA, et al.
Medical mycology 2020; (58(2)):172-180 doi:10.1093/mmy/myz034.
PMID: 31329924 - 2
[Management of chromoblastomycosis, a challenge for limited-resource countries such as Madagascar].
Sendrasoa FA, Rakotoarisaona MF, Ranaivo IM, et al.
Annales de dermatologie et de venereologie 2020; (147(5)):377-382 doi:10.1016/j.annder.2020.01.018.
PMID: 32220474 - 3
Establishment of epidemiological cutoff values for Fonsecaea pedrosoi, the primary etiologic agent of chromoblastomycosis, and eight antifungal medications.
Smith DJ, Melhem MSC, Dirven J, et al.
Journal of clinical microbiology 2025; (63(5)):e0190324 doi:10.1128/jcm.01903-24.
PMID: 40183549 - 4
Case for diagnosis. Pruritic erythematosquamous lesion in the auricle.
Melo ED, Morais PM, Fernandes DCL, Rebello PFB
Anais brasileiros de dermatologia 2020; (95(4)):521-523 doi:10.1016/j.abd.2019.11.011.
PMID: 32473772 - 5
Chromoblastomycosis in Taiwan: A report of 30 cases and a review of the literature.
Yang CS, Chen CB, Lee YY, et al.
Medical mycology 2018; (56(4)):395-405 doi:10.1093/mmy/myx075.
PMID: 29087525 - 6
Chromoblastomycosis in French Guiana: Epidemiology and Practices, 1955-2023.
Valentin J, Grotta G, Muller T, et al.
Journal of fungi (Basel, Switzerland) 2024; (10(3)) doi:10.3390/jof10030168.
PMID: 38535177 - 7
CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE.
Queiroz-Telles F
Revista do Instituto de Medicina Tropical de Sao Paulo 2015; (57 Suppl 19()):46-50.
PMID: 26465369 - 8
Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.
Popovic K, Henao-Martínez AF, Teixeira MM, et al.
Current fungal infection reports 2026; (20()) doi:10.1007/s12281-026-00532-3.
PMID: 42099658 - 9
A Case of Recurrent Chromoblastomycosis Treated with Multiple Surgical Management Options.
Kelly M, Williams C, Miller R
Dermatopathology (Basel, Switzerland) 2026; (13(1)) doi:10.3390/dermatopathology13010010.
PMID: 41892077 - 10
Chromoblastomycosis in India: Review of 169 cases.
Agarwal R, Singh G, Ghosh A, et al.
PLoS neglected tropical diseases 2017; (11(8)):e0005534 doi:10.1371/journal.pntd.0005534.
PMID: 28771470 - 11
Chromoblastomycosis: A Case Series and Literature Review.
Shenoy MM, Girisha BS, Krishna S
Indian dermatology online journal 2023; (14(5)):665-669 doi:10.4103/idoj.idoj_292_23.
PMID: 37727562 - 12
Successful treatment of chromoblastomycosis of 10-year duration due to Fonsecaea nubica.
He L, Ma J, Mei X, et al.
Mycoses 2018; (61(4)):231-236 doi:10.1111/myc.12732.
PMID: 29178398 - 13
Electric Heating Pad as an Adjuvant Treatment of Extensive Chromoblastomycosis in Immunocompetent Patient: A Case Report.
Hidayah RMN, Gunawan H, Fauziah N, Rianty F
International medical case reports journal 2025; (18()):315-320 doi:10.2147/IMCRJ.S507453.
PMID: 40078837 - 14
Retinoid combined with photodynamic therapy against hyperkeratotic chromoblastomycosis: A case report and literature review.
Lan Y, Lu S, Zhang J
Mycoses 2021; (64(1)):18-23 doi:10.1111/myc.13190.
PMID: 32989774 - 15
Combination therapy for an elderly patient with chromoblastomycosis caused by Fonsecaea monophora: a case report.
Shen Y, Jiang B, Zhang H, et al.
Annals of translational medicine 2022; (10(2)):114 doi:10.21037/atm-21-6119.
PMID: 35282094 - 16
Nodular lesions of the buttock for 20 years: the challenge of chromoblastomycosis in non-endemic settings.
Osborne W, Langman G, Ladoyanni E, Chue A
BMJ case reports 2024; (17(3)) doi:10.1136/bcr-2023-258097.
PMID: 38490708 - 17
Chromoblastomycosis is curable with DAT therapy (debulking, intralesional amphotericin B, oral terbinafine); case series of 16 patients.
Ranawaka RR, Abeywickrama V
Indian journal of pharmacology 2024; (56(6)):437-439 doi:10.4103/ijp.ijp_397_24.
PMID: 39973833
This page is for informational purposes only and does not constitute medical advice. Antifungal treatment and physical therapies for chromoblastomycosis should be selected and monitored by your dermatologist or infectious-disease clinician.